journal
MENU ▼
Read by QxMD icon Read
search

American Journal of Clinical Dermatology

journal
https://www.readbyqxmd.com/read/29230666/granuloma-annulare-a-focused-review-of-therapeutic-options
#1
REVIEW
Jenny Wang, Amor Khachemoune
Granuloma annulare (GA) is a benign inflammatory disease associated with many conditions such as malignancy, trauma, thyroid disease, diabetes mellitus, and HIV infection. Common clinical subtypes include localized GA, generalized GA, subcutaneous GA, perforating GA, and patch GA. There exists an abundance of literature on GA, yet we know relatively little about its exact etiology and even less about its treatment. The paucity of conclusive data on effective treatment options is largely because the majority of published studies are limited to small case reports, case series, and retrospective studies...
December 11, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29222629/postinflammatory-hyperpigmentation-epidemiology-clinical-presentation-pathogenesis-and-treatment
#2
REVIEW
Bridget P Kaufman, Taulun Aman, Andrew F Alexis
Postinflammatory hyperpigmentation (PIH) is a reactive hypermelanosis that develops following cutaneous inflammation. Common causes of PIH include intrinsic skin conditions (e.g., acne and eczema) as well as external insults to the skin, such as burn injuries and dermatologic procedures. PIH more commonly occurs in individuals with darker skin, for whom it is often a source of significant psychological distress. Several therapeutic modalities are available for the treatment of PIH, including topical agents, chemical peels, and energy-based devices...
December 8, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29209945/psoriasis-in-skin-of-color-insights-into-the-epidemiology-clinical-presentation-genetics-quality-of-life-impact-and-treatment-of-psoriasis-in-non-white-racial-ethnic-groups
#3
REVIEW
Bridget P Kaufman, Andrew F Alexis
Psoriasis is a chronic inflammatory skin condition affecting diverse racial/ethnic groups throughout the world. Large population-based studies suggest that psoriasis occurs most often in individuals of European ancestry, followed by black and Hispanic individuals, although the true prevalence of psoriasis in non-white individuals is likely underestimated. Despite similarities in psoriasis between ethnic groups, there are notable differences in the presentation, quality-of-life impact, and treatment of psoriasis with important implications for the management of non-white individuals...
December 5, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29164492/advanced-melanoma-current-treatment-options-biomarkers-and-future-perspectives
#4
REVIEW
Elisa A Rozeman, Tim J A Dekker, John B A G Haanen, Christian U Blank
Malignant melanoma accounts for the highest number of deaths from skin cancer, and the prognosis of patients with stage IV disease has historically been poor. Novel insights into both mutations driving tumorigenesis and immune escape mechanisms of these tumors have led to effective treatment options that have revolutionized the treatment of this disease. Targeting the MAPK kinase pathway (with BRAF and MEK inhibitors), as well as targeting checkpoints, such as cytotoxic T-lymphocyte associated protein 4 (CTLA-4) or programmed death 1 (PD-1), have improved overall survival in patients with late-stage melanoma, and biomarker research for personalized therapy is ongoing for each of these treatment modalities...
November 21, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29139054/poland-s-syndrome-are-postzygotic-mutations-in-%C3%AE-actin-associated-with-its-pathogenesis
#5
LETTER
Philip R Cohen
No abstract text is available yet for this article.
November 14, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29098604/are-biologics-efficacious-in-atopic-dermatitis-a-systematic-review-and-meta-analysis
#6
REVIEW
Igor Snast, Ofer Reiter, Emmilia Hodak, Rivka Friedland, Daniel Mimouni, Yael Anne Leshem
BACKGROUND: Current systemic treatments for atopic dermatitis (AD) offer limited efficacy and are often restricted by safety concerns. Biologics may address the unmet need for improved AD therapeutics. OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of biologic agents in AD. METHODS: A systematic review and meta-analysis of studies evaluating AD patients treated with biologics was performed. The primary outcome was the Eczema Area and Severity Index (EASI)-75 response, while secondary outcomes were SCOring Atopic Dermatitis (SCORAD)-75, EASI-50, SCORAD-50, Investigator Global Assessment 0/1 responses, change in responses from baseline, and adverse events...
November 2, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29080066/choosing-first-line-biologic-treatment-for-moderate-to-severe-psoriasis-what-does-the-evidence-say
#7
Mina Amin, Daniel J No, Alexander Egeberg, Jashin J Wu
An advanced understanding of the pathogenesis of psoriasis has led to the development of multiple therapeutic options for moderate-to-severe psoriasis. Tumor necrosis factor inhibitors, ustekinumab, interleukin-17 inhibitors, and guselkumab (an interleukin-23 inhibitor recently approved for psoriasis) are commercially available biologic agents for psoriasis. Evidence from clinical trials provides pertinent information regarding the safety and efficacy of biologic agents for psoriasis, which should be integrated into clinical decision making...
October 27, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29076116/crisaborole-ointment-2-a-review-in-mild-to-moderate-atopic-dermatitis
#8
Sheridan M Hoy
Crisaborole ointment 2% (Eucrisa™) is a novel, anti-inflammatory inhibitor of phosphodiesterase 4 (PDE4) that is available in the USA for the topical treatment of mild to moderate atopic dermatitis in patients aged ≥ 2 years. In two short-term (28 days), identically designed, multicentre, phase III studies in this patient population, topical therapy with crisaborole ointment 2% reduced disease severity and pruritus severity compared with vehicle, with the effect established early and sustained over the course of treatment...
October 26, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28994020/vitamin-d-and-the-skin-an-update-for-dermatologists
#9
REVIEW
Elio Kechichian, Khaled Ezzedine
Vitamin D plays a key role in skeletal and cardiovascular disorders, cancers, central nervous system diseases, reproductive diseases, infections, and autoimmune and dermatological disorders. The two main sources of vitamin D are sun exposure and oral intake, including vitamin D supplementation and dietary intake. Multiple factors are linked to vitamin D status, such as Fitzpatrick skin type, sex, body mass index, physical activity, alcohol intake, and vitamin D receptor polymorphisms. Patients with photosensitive disorders tend to avoid sun exposure, and this practice, along with photoprotection, can put this category of patients at risk for vitamin D deficiency...
October 9, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28993993/a-practical-guide-about-tattooing-in-patients-with-chronic-skin-disorders-and-other-medical-conditions
#10
Nicolas Kluger, Christa De Cuyper
With tattoos becoming increasingly mainstream, dermatologists are more and more often consulted by patients who are considering getting an ornamental, cosmetic, or even a medical tattoo, and who subsequently ask for advice. This includes not only patients with chronic skin diseases such as psoriasis or atopic dermatitis but also patients with other medical conditions. This review first explores the reasons why patients may want to get a tattoo and aims to offer some key information to dermatologists on what they should know about tattooing and the main risks associated with this procedure...
October 9, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28597181/clinical-signs-pathophysiology-and-management-of-cutaneous-side-effects-of-anti-tumor-necrosis-factor-agents
#11
REVIEW
Siegfried Segaert, Caroline Hermans
Approximately one in four patients treated with anti-TNF agents (infliximab, etanercept, adalimumab, certolizumab, and golimumab) develops cutaneous adverse events, typically months to years after the initiation of treatment, with xerosis cutis, eczema (often psoriasiform), psoriasis, palmoplantar pustulosis, cutaneous infections, alopecia, and skin cancer being the most frequently encountered. The typical skin lesion of anti-tumor necrosis factor (TNF)-treated patients is orange-red psoriasiform eczema affecting the flexures, genitalia, scalp, or face, with high susceptibility to bacterial superinfection with Staphylococcus aureus...
December 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28477309/oral-ulcers-in-juvenile-onset-systemic-lupus-erythematosus-a-review-of-the-literature
#12
REVIEW
Pongsawat Rodsaward, Titipong Prueksrisakul, Tawatchai Deekajorndech, Steven W Edwards, Michael W Beresford, Direkrit Chiewchengchol
Oral ulcers are the most common mucosal sign in juvenile-onset systemic lupus erythematosus (JSLE). The ulcers are one of the key clinical features; however, the terminology of oral ulcers, especially in JSLE patients, is often vague and ill-defined. In fact, there are several clinical manifestations of oral ulcers in JSLE, and some lesions occur when the disease is active, indicating that early management of the disease should be started. Oral ulcers are classified as lupus erythematosus (LE) specific, where the lesional biopsy shows a unique pattern of mucosal change in LE, and LE nonspecific, where the ulcers and their histopathological findings can be found in other oral diseases...
December 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28447213/discordance-between-physician-and-patient-reported-disease-severity-in-adults-with-atopic-dermatitis-a-us-cross-sectional-survey
#13
Wenhui Wei, Peter Anderson, Abhijit Gadkari, Stuart Blackburn, Rachel Moon, James Piercy, Shashank Shinde, Jorge Gomez, Eric Ghorayeb
BACKGROUND: There is limited understanding of severity rating of atopic dermatitis in clinical practice. OBJECTIVES: To evaluate the agreement between physician- and patient-rated severity of atopic dermatitis. METHODS: Data were collected from the 2014 Adelphi US Atopic Dermatitis Disease Specific Programme, a cross-sectional survey of physicians and their patients with a history of moderate-to-severe atopic dermatitis; patients voluntarily completed a questionnaire...
December 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28432649/psoriasis-depression-and-inflammatory-overlap-a-review
#14
Nupur Patel, Anish Nadkarni, Leah A Cardwell, Nora Vera, Casey Frey, Nikhil Patel, Steven R Feldman
Psoriasis has an enormous impact on patients' lives and is frequently associated with depression. Depression in psoriasis may be attributed, at least in part, to elevated proinflammatory cytokines rather than the psychosocial impact of psoriasis itself. Biologics that target inflammatory cytokines treat the clinical manifestations of psoriasis, but may also play a role in reducing associated depression. Multiple biologics have decreased symptoms of depression during clinical trials in psoriasis; however, these studies used a variety of depression screening tools, which limits comparison...
October 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28921458/pharmacogenetics-and-pharmacogenomics-in-moderate-to-severe-psoriasis
#15
REVIEW
María C Ovejero-Benito, Ester Muñoz-Aceituno, Alejandra Reolid, Miriam Saiz-Rodríguez, Francisco Abad-Santos, Esteban Daudén
Pharmacogenetics is the study of variations in DNA sequence related to drug response. Moreover, the evolution of biotechnology and the sequencing of human DNA have allowed the creation of pharmacogenomics, a branch of genetics that analyzes human genes, the RNAs and proteins encoded by them, and the inter-and intra-individual variations in expression and function in relation to drug response. Pharmacogenetics and pharmacogenomics are being used to search for biomarkers that can predict response to systemic treatments, including those for moderate-to-severe psoriasis...
September 18, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28891036/acne-scars-how-do-we-grade-them
#16
Ashley K Clark, Suzana Saric, Raja K Sivamani
Acne vulgaris is a chronic inflammatory skin disease that can lead to permanent scarring. Although grading scales exist for acne scarring, there are many limitations, and there is still a need for a well validated gold standard scale for use in clinical practice or research trials. An objective measure of scar severity should be a component of global acne severity evaluations. This manuscript reviews currently available acne scar grading modalities: lesion counting; subjective self-assessment; Acne Scar Rating Scale (ASRS); evaluator-based qualitative and quantitative scarring grading systems; Echelle d'Evaluation Clinique des Cicatrices d'acne (ECCA); Global Scale for Acne Scar Severity (SCAR-S); and imaging...
September 11, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28887802/small-molecule-inhibitors-of-the-hedgehog-pathway-in-the-treatment-of-basal-cell-carcinoma-of-the-skin
#17
REVIEW
Rebecca Danhof, Karl Lewis, Mariah Brown
Basal cell carcinoma (BCC) is the most common type of skin cancer, with rising incidence rates primarily attributed to an aging population and ultraviolet radiation exposure. While the majority of BCCs are localized and respond to standard therapies, a very small minority of these tumors become locally destructive or metastasize. These advanced BCCs may not be amenable to localized treatment with surgery and/or radiation therapy. Most BCCs result from mutations in key receptors in the Hedgehog (HH) signaling pathway...
September 8, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28871562/teledermatology-a-review-and-update
#18
REVIEW
Jonathan J Lee, Joseph C English
Telemedicine is slowly transforming the way in which healthcare is delivered and has the potential to improve access to subspecialty expertise, reduce healthcare costs, and improve the overall quality of care. While many subspecialty fields within medicine today have either experimented with or begun to implement telemedicine platforms to enable remote consultation and care, dermatology is particularly suited for this care system as skin disorders are uniquely visible to the human eye. Through teledermatology, diagnostic images of skin disorders with accompanying clinical histories can be remotely reviewed by teledermatologists by any number of modalities, such as photographic clinical images or live video teleconferencing...
September 4, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28861871/combinatorial-therapies-in-melanoma-mapk-inhibitors-and-beyond
#19
REVIEW
Alice Y Zhou, Douglas B Johnson
Melanoma is the most aggressive of the skin cancers, with historically high rates of morbidity and mortality due to its resistance to traditional cytotoxic therapies. Recently, however, breakthroughs in new therapies have dramatically changed clinical outcomes of this disease. These advances emerged from an improved understanding of tumor oncogenesis and the interacting tumor microenvironment. Small molecules that target the oncogenic mitogen-activated protein kinase (MAPK) pathway, specifically the tyrosine kinase BRAF and its downstream signaling partner MEK, have demonstrated an improved overall survival and progression-free survival for BRAF-mutant melanoma...
August 31, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28849428/topical-corticosteroid-concerns-among-parents-of-children-with-psoriasis-versus-atopic-dermatitis-a-french-multicenter-cross-sectional-study
#20
Sandra Moawad, Emmanuel Mahé, Hélène Aubert-Wastiaux, Alice Phan, Annabel Maruani, Christine Chiaverini, Christine Bodemer, Juliette Mazereeuw-Hautier, Audrey Lasek-Duriez, Catherine Droitcourt, Sébastien Barbarot, Alain Beauchet, Anne-Claire Bursztejn
BACKGROUND: Atopic dermatitis (AD) and psoriasis are chronic inflammatory cutaneous disorders for which the gold standard treatment is topical corticosteroids. Although fears about topical corticosteroids are known to be a primary cause of poor therapeutic adherence in AD, this has not been evaluated in psoriasis. TOPICOP is a helpful and easy-to-use tool for the evaluation of topical corticosteroid concerns (TCC). It may help clinicians improve adherence to treatment and correct misconceptions...
August 28, 2017: American Journal of Clinical Dermatology
journal
journal
34795
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"